Abstract
In the end of last year, the US Food and Drug Administration has announced the authorization of MSK-IMPACT™, clinical test based on multiplex cancer panel profiling for genetic mutations and other alterations in patients' tumors, while in Japan, NCC Oncopanel, domestic multiplex cancer panel, is scheduled to be clinically implemented as advanced medical care B in this coming spring, chasing the state of the art technology for cancer treatment. In this article, we outline a recently published roadmap for precision medicine in Japan, together with our years of experience on cancer diagnosis and treatment based on multiplex cancer panel at Okayama University Hospital and Okadai Biobank.
| Original language | English |
|---|---|
| Pages (from-to) | 601-604 |
| Number of pages | 4 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 45 |
| Issue number | 4 |
| Publication status | Published - Apr 2018 |
Keywords
- Cancer treatment
- Genetic mutation
- Multiplex cancer panel
- Precision medicine
ASJC Scopus subject areas
- Oncology
- Cancer Research
